Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06910839 · ClinicalTrials.gov registry record · Phase 1
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT06910839 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 21 participants.
The verdict
NCT06910839, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity. The total number of weeks of the study is up to approximately 22 weeks (5.5 months).
Interventions
- DRUG PF-06882961
- DRUG PF-07976016
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2025-05-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06910839
The ClinicalTrials.gov registry entry for NCT06910839 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-06882961 is the first listed.
NCT06910839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06910839 about?
NCT06910839 is a clinical study titled "Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity". The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity. The total number of weeks of the study is up to approximately 22 weeks (5.5 months).
What is the current status of trial NCT06910839?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2025-03-13. Estimated completion is 2025-05-20.
What interventions are being tested in trial NCT06910839?
The interventions under investigation include: PF-06882961 (DRUG), PF-07976016 (DRUG).
Who is sponsoring clinical trial NCT06910839?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.